AstraZeneca Pharma India received CDSCO approval on April 9, 2026 for additional indication of Acalabrutinib tablets 100mg (Calquence®).
Approval covers combination treatment for previously untreated chronic lymphocytic leukaemia/small lymphocytic lymphoma patients.
Permission enables marketing of Calquence® for specified additional indication in India, subject to statutory approvals.